

Équipe de recherche « Nuclear Organization and Post-Translational Control in Physio-Pathology »

Centre interdisciplinaire de recherche en biologie (CIRB)

SÉLECTION DE PUBLICATIONS (2014-2025)

1. Ablain, J., K. Rice, H. Soilihi, A. de Reynies, S. Minucci, and H. de The, *Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure*. **Nature medicine**, 2014. 20: p. 167-74.
2. Lehmann-Che, J., C. Bally, and H. de The, *therapy resistance in APL*. **New Engl. J. Med.**, 2014. 371: p. 1171-1172.
3. Sahin, U., O. Ferhi, M. Jeanne, S. Benhenda, C. Berthier, F. Jollivet, M. Niwa-Kawakita, O. Faklaris, N. Setterblad, H. de The, and V. Lallemand-Breitenbach, *Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins*. **The Journal of cell biology**, 2014. 204(6): p. 931-45.
4. Vitaliano-Prunier, A., J. Halftermeyer, J. Ablain, A. de Reynies, L. Peres, M. Le Bras, D. Metzger, and H. de The, *Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation*. **Blood**, 2014. 124(25): p. 3772-80.
5. Ivanschitz, L., Y. Takahashi, F. Jollivet, O. Ayrault, M. Le Bras, and H. de The, *PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence*. **Proc Natl Acad Sci U S A**, 2015. 112(46): p. 14278-83.
6. de The, H., P.P. Pandolfi, and Z. Chen, *Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure*. **Cancer Cell**, 2017. 32(5): p. 552-560.
7. Niwa-Kawakita, M., O. Ferhi, H. Soilihi, M. Le Bras, V. Lallemand-Breitenbach, and H. de The, *PML is a ROS sensor activating p53 upon oxidative stress*. **J Exp Med**, 2017. 214(11): p. 3197-3206.
8. de The, H., *Differentiation therapy revisited*. **Nat Rev Cancer**, 2018. 18(2): p. 117-127.

9. Lallemand-Breitenbach, V. and H. de The, *PML nuclear bodies: from architecture to function*. **Curr Opin Cell Biol**, 2018. 52: p. 154-161.
10. Lehmann-Che, J., C. Bally, E. Letouze, C. Berthier, H. Yuan, F. Jollivet, L. Ades, B. Cassinat, P. Hirsch, A. Pigneux, M.J. Mozziconacci, S. Kogan, P. Fenaux, and H. de The, *Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia*. **Nat Commun**, 2018. 9(1): p. 2047.
11. Wang, P., S. Benhenda, H. Wu, V. Lallemand-Breitenbach, T. Zhen, F. Jollivet, L. Peres, Y. Li, S.J. Chen, Z. Chen, H. de The, and G. Meng, *RING tetramerization is required for nuclear body biogenesis and PML sumoylation*. **Nat Commun**, 2018. 9(1): p. 1277.
12. Esnault, C., R. Rahme, K.L. Rice, C. Berthier, C. Gaillard, S. Quentin, A.L. Maubert, S. Kogan, and H. de The, *FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias*. **Blood**, 2019. 133(13): p. 1495-1506.
13. Dagher, T., N. Maslah, V. Edmond, B. Cassinat, W. Vainchenker, S. Giraudier, F. Pasquier, E. Verger, M. Niwa-Kawakita, V. Lallemand-Breitenbach, I. Plo, J.J. Kiladjian, J.L. Villeval, and H. de The, *JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML*. **J Exp Med**, 2021. 218(2).
14. Geoffroy, M.C., c. Esnault, and H. de The, *Retinoids in haematology, a timely revival ?*. **Blood**, 2021. 137(18): p. 2429-2437.
15. Wu, H.C., D. Rerolle, C. Berthier, R. Hleihel, T. Sakamoto, S. Quentin, S. Benhenda, C. Morganti, C.C. Wu, L. Conte, S. Rimsky, M. Sebert, E. Clappier, S. Souquere, S. Gachet, J. Soulier, S. Durand, J.J. Trowbridge, P. Benit, P. Rustin, H. El Hajj, E. Raffoux, L. Ades, R. Itzykson, H. Dombret, P. Fenaux, O. Espeli, G. Kroemer, L. Brunetti, T.W. Mak, V. Lallemand-Breitenbach, A. Bazarbachi, B. Falini, M.F. Martelli, and H. de The, *Actinomycin D targets NPM1c-primed mitochondria to restore PML- driven senescence in AML therapy*. **Cancer Discov**, 2021. 11(12): p. 3198-3213.
16. Tessier, S., O. Ferhi, M.C. Geoffroy, R. Gonzalez-Prieto, A. Canat, S. Quentin, M. Pla, M. Niwa-Kawakita, P. Bercier, D. Rerolle, M. Tirard, P. Therizols, E. Fabre, A.C.O. Vertegaal, H. de The*, and V. Lallemand-Breitenbach*, *Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells*. **Nat Commun**, 2022. 13(1): p. 5726.
17. Bercier, P., Q.Q. Wang, N. Zang, J. Zhang, C. Yang, Y. Maimaitiyiming, M. Abou-Ghali, C. Berthier, C. Wu, M. Niwa-Kawakita, T. Dirami, M.C. Geoffroy, O. Ferhi, S. Quentin, S. Benhenda, Y. Ogra, Z. Gueroui, C. Zhou, H. Naranmandura, H. de The*, and V. Lallemand-Breitenbach*, *Structural basis of PML/RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function*. **Cancer Discov**, 2023. 3(12):2548-2565.

18. Rerolle, D. and H. de Thé, *The PML hub: An emerging actor of leukemia therapies*. **J Exp Med**, 2023. 220(8).
19. R  rolle D, Wu HC, de Th   H. *Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities*. **Cold Spring Harb Perspect Med**. 2024. 14(9):a041582.
20. Letai, A and de Th  , H *Conventional chemotherapy: millions of cures, unresolved therapeutic index*. **Nat Rev Cancer** 2025. (3):209-218